title: The regulatory sciences for stem cell-based medicinal products.
abstract: Over the past few years, several new achievements have been made from stem cell studies, many of which have moved up from preclinical stages to early, or from early to middle or late, stages thanks to relatively safe profile and preliminary evidence of effectiveness. Moreover, some stem cell-based products have been approved for marketing by different national regulatory authorities. However, many critical issues associated mainly with incomplete understanding of stem cell biology and the relevant risk factors, and lack of effective regulations still exist and need to be urgently addressed, especially in countries where establishment of appropriate regulatory system just commenced. More relevantly, the stem cell regulatory sciences need to be established or improved to more effectively evaluate quality, safety and efficacy of stem cell products, and for building up the appropriate regulatory framework. In this review, we summarize some new achievements in stem cell studies, especially the preclinical and clinical studies, the existing regulations, and the associated challenges, and we then propose some considerations for improving stem cell regulatory sciences with a goal of promoting the steadfast growth of the well-regulated stem cell therapies abreast of evolvement of stem cell sciences and technologies.
authors.affiliation: National Institutes for Food and Drug Control, Beijing, 100050, China.
authors.forename: Bao-Zhu
authors.initials: BZ
authors.lastname: Yuan
authors.forename: Junzhi
authors.initials: J
authors.lastname: Wang
mesh_terms: D001688:Biological Products / Q000378:metabolism*; D002681:China; D033161:Government Regulation; D006801:Humans; D007880:Legislation, Drug; D011786:Quality Control; D057905:Stem Cell Research / Q000331:legislation & jurisprudence*; D013234:Stem Cells / Q000378:metabolism*
chemical_list: D001688:Biological Products
references.citation: Blood. 2010 Feb 25;115(8):1549-53
references.pmid: 20032501
references.citation: Nat Biotechnol. 2010 Apr;28(4):371-7
references.pmid: 20351689
references.citation: Stem Cells. 2012 Jul;30(7):1565-74
references.pmid: 22522999
references.citation: Cytotherapy. 2006;8(4):315-7
references.pmid: 16923606
references.citation: Blood. 2007 Aug 15;110(4):1362-9
references.pmid: 17483296
references.citation: J Transl Med. 2011 Mar 22;9:29
references.pmid: 21418664
references.citation: Stem Cells. 2010 May;28(5):996-1004
references.pmid: 20333747
references.citation: Regen Med. 2010 Jan;5(1):35-44
references.pmid: 20055687
references.citation: Regen Med. 2012 Nov;7(6 Suppl):12-4
references.pmid: 23210807
references.citation: Regen Med. 2012 Nov;7(6 Suppl):89-92
references.pmid: 23210818
references.citation: Vaccine. 2013 Apr 18;31 Suppl 2:B163-75
references.pmid: 23598478
references.citation: Curr Mol Med. 2012 Jun;12(5):574-91
references.pmid: 22515979
references.citation: Biol Blood Marrow Transplant. 2011 Apr;17(4):534-41
references.pmid: 20457269
references.citation: Regen Med. 2012 Nov;7(6 Suppl):26-31
references.pmid: 23210808
references.citation: J Biomed Biotechnol. 2011;2011:459510
references.pmid: 21822372
references.citation: Regen Med. 2012 Nov;7(6 Suppl):120-3
references.pmid: 23210824
references.citation: Regen Med. 2012 Nov;7(6 Suppl):50-6
references.pmid: 23210811
references.citation: Regen Med. 2012 Nov;7(6 Suppl):17-24
references.pmid: 23346572
references.citation: Regen Med. 2012 Nov;7(6 Suppl):32-9
references.pmid: 23210809
references.citation: Stem Cells. 2008 Jun;26(6):1387-94
references.pmid: 18388305
references.citation: Cytotherapy. 2013 Sep;15(9):1054-61
references.pmid: 23602578
references.citation: Regen Med. 2012 Nov;7(6 Suppl):100-3
references.pmid: 23210820
references.citation: Perspect Clin Res. 2011 Jul;2(3):94-9
references.pmid: 21897884
references.citation: Exp Gerontol. 2008 Nov;43(11):1018-23
references.pmid: 18694815